http___bg.gsk.com_bg-bg__D0_BE_D1_82_D0_B3_D0_BE_D0_B2_D0_BE_D1_80_D0_BD_D0_BE_D1_81_D1_82__D0_B0_D0_BD_D0_B3_D0_B0_D0_B6_D0_B8_D1_80_D0_B0_D0_BD_D0_B5-_D0_BD_D0_B0-_D0_BC_D0_B5_D0_B4_D0_B8_D1_86_D0_B8_D0_BD_D1_81_D0_BA_D0_B8-_D1_81_D0_BF_D0_B5_D1_86_D0_B8_D0_B0_D0_BB_D0_B8_D1_81_D1_82_D0_B8-_D0_BD_D0_B0_D1_88_D0_B8_D1_8F_D1_82-_D0_BF_D0_BE_D0_B4_D1_85_D0_BE_D0_B4__2.xml
1.1 2.1 2.2 3.1 4.1 4.2 4.3 5.1 6.1 6.2 6.3 6.4 6.5 6.6 7.1 8.1 8.2 8.3 9.1 9.2 9.3 10.1
Ангажиране на медицински специалисти (нашият подход) GSK България oповестява информация за трансфери на стойност направени към медицински специалисти и здравни организации, в съответствие с изискванията за прозрачност на кодекса за оповестяване на Европейската федерация на фармацевтичните индустрии и асоциации (EFPIA). Вярваме, че тези данни ще създадат по-добро разбиране за начина, по който работим с медицински специалисти и здравни организации и ще повишат доверието в работата ни с тях, за да предоставим подобрено здравеопазване в най-добрия интерес на пациентите. Оповестяване на плащания извършвани към медицински специалисти в България През последните години GSK поставя предизвикателство пред традиционния търговски модел на фармацевтичните компании, чрез водещи в отрасъла подобрения в начина на правене на бизнес. Нашите подобрения имат за цел да отговорят на нарастващото очакване на обществото за прозрачност в действията на организации и лица. Това включва взаимоотношенията ни с медицинските специалисти (МС) или здравните организации (ЗО), така че всички тези взаимодействия да се поддържат в почтеност и прозрачност. Ние напълно подкрепяме Кодекса на Европейската федерация на фармацевтичните индустрии и асоциации (EFPIA) за разкриването на индивидуалните трансфери на стойност от фармацевтични компании към здравни специалисти и здравни организации. Считано от 01.01.2016 г. GSK преустанови плащания към медицински специалисти, които говорят за нашите лекарства с рецепта или ваксини, включително пред лица, които могат да предписват или да влияят върху предписването. От януари 2016 г. GSK престава да осигурява и финансова подкрепа директно на отделните медицински специалисти за участие в медицински конгреси. Тези промени изпреварват текущите кодекси в отрасъла и следователно изпреварват и другите в индустрията. Продължаваме да работим с медицинските специалисти за непромоционални дейности, като например клинични проучвания. Съгласно кодекса, и до 30.06.2016 г., фирмите членуващи в EFPIA в цяла Европа, включително и GSK, се ангажират да публикуват индивидуалните трансфери на стойност направени през 2015 г., към МС и ЗО във връзка с лекарствата по лекарско предписание за всяко лице поотделно (като групирането е само по изключение). Оповестяването включва, например, спонсорство за пътуване и регистрационни такси за участие в медицински конгреси, консултантски хонорари на МС за изнасяне на лекции или за водене на заседания, както и спонсорства и дарения към ЗО. Трансфери на стойност към МС и ЗО за дейности свързани с научноизследователска и развойна дейност ще се оповестяват като обобщено число. Оповестяването, което правим през месец юни 2016 г. съгласно кодекса на EFPIA се отнася за 2015 г., преди GSK да е преустановила плащанията към лекторите-медицински специалисти. Вярваме, че това оповестяване ще допринесе за създаването на по-добро разбиране за начина, по който фармацевтичната индустрия работи с МС и ЗО. Като се имат предвид мерките, които GSK е въвела, ние се стремим да повишим доверието в медицинската професия и разбирането за това как и защо работим с тях за устойчиво подобряване на здравеопазването и в най-добрия интерес на пациентите. Повече информация за нашия подход към кодекса на EFPIA, за това как водим подобренията на практиките в отрасъла, както и значението на нашите партньорства МС и ЗО може да се открие по-долу и е изложена в по-големи подробности тук. Нашето оповестяване за България може да се види тук.
1.1 2.1 2.2 3.1 3.2 4.1 5.1 5.2 5.3 5.4 5.5 6.1 7.1 7.2 7.3 7.4 8.1 8.2 8.3 9.1 10.1 11.1 12.1 12.2 13.1 14.1 15.1 16.1 17.1 17.2 18.1 19.1 20.1 21.1 23.1 24.1 26.1 27.1 29.1 30.1 32.1 33.1 34.1 35.1 35.2 35.3 36.1 36.2 36.3 37.1 38.1 39.1 40.1 41.1 43.1 44.1 46.1 47.1 49.1 50.1 52.1 53.1
Europe In Europe, and around the world, there is a growing expectation in society that companies, organisations and individuals act in a transparent manner. This applies to relationships between the pharmaceutical industry, healthcare professionals (HCPs) and healthcare organisations (HCOs) where all interactions should be conducted with integrity and transparency. GSK fully supports the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on the disclosure of individual transfer of value from pharmaceutical companies to healthcare professionals and healthcare organisations. We believe that it helps to create a better understanding about how the pharmaceutical industry partners and collaborates with HCPs and HCOs, and so increase confidence in the way that industry and the healthcare professions works together. The importance of industry collaboration with HCPs Cooperation between pharmaceutical companies, regulators, HCPs, HCOs and patients, is essential for the sustainable improvement of healthcare. These relationships have helped deliver numerous innovative new medicines and changed the way many diseases impact on our lives. HCPs have always been and will always remain valuable partners for GSK. As experts in their field, they provide us with first hand scientific and medical knowledge and unique insights into patient care. This partnership is fundamental to the progression of medical science, helping to meet disparate patient and public health needs. Supporting greater transparency in Europe Over the past few years we have begun to disclose information, on an individual or aggregate basis, regarding transfers of value made to HCPs and HCOs in a number of countries. This involves 30 European countries plus Russia and Ukraine. Internationally, it includes Australia, Japan, the USA and Canada. The EFPIA disclosure initiative builds on these national initiatives, as part of an evolution towards greater transparency. Under the EFPIA Disclosure Code, from 2016 EFPIA member companies pledged to disclose the transfers of value they make to HCPs and HCOs in connection with prescription medicines, on an individual named basis (aggregate by exception only). This includes, for example, sponsorship for travel and registration fees to attend medical congresses, HCP consultancy fees for speaker arrangements or for chairing meetings and grants to HCOs. Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number. Disclosure information is published annually in most cases (covering the previous year) on a public platform; either the company’s own website or, in some countries, a central platform combining data from different companies. Our approach to EFPIA disclosure As part of our goal to be one of the most innovative, best performing and trusted healthcare companies in the world, we seek to meet society’s evolving expectations, bring greater transparency to an already well-regulated industry, and strengthen or relationships with HCPs and HCOs for future collaboration. We also recognise the need to further increase transparency and public confidence in our business. That is why we continue to implement the EFPIA Disclosure Code in the true spirit in which it is intended; which means we will strive to named individual disclosure where required under the Code as the rule and disclose on an aggregate basis only for payments relating to Research and Development (as stipulated under the EFPIA Disclosure Code) or otherwise by exception. Going beyond transparency We have committed to going beyond the requirements set out in the EFPIA Disclosure Code by continuing to make additional, industry leading changes to our business model, including: - Changing the way our Sales Representatives are compensated by removing individual sales targets; - Stopping payments to HCPs to speak about our prescription medicines and disease areas in promotional, non-medical settings. Instead, we have introduced new ways of delivering information to HCPs, including digital and real-time applications to improve delivery of medical information. We will continue to work with and pay HCPs for non-promotional activities including the conduct of clinical research and seeking advice on the clinical relevance and appropriate communication of the results of our research, as well as identifying new research areas. These interactions are an essential part of how we ensure medicines we develop meet patients’ needs. What does this mean for patients? We believe our continued commitment to greater transparency and ways of working with HCPs help to provide greater confidence that industry is acting in the best interests of patients and an improved understanding about the importance of collaboration between pharmaceutical companies and the medical profession. Find out more USA We were one of the first pharmaceutical companies in the USA to voluntarily disclose information about our work with physicians Rest of the world We continue to support and work towards transparency as industry associations or governments establish specific guidelines for disclosure around the world Compassionate use (Expanded access) Our policy explains our position and criteria for assessing requests and provides a link for health care professionals’ requests. Our behaviour We are changing the way we work to further embed our values in everything we do, including the way we research, develop, sell and market our products We have published disclosure reports in line with the EFPIA Code on the disclosure of individual transfers of value from pharmaceutical companies to healthcare professionals and healthcare organisations. Click on the appropriate section in the table below to view GSK’s disclosure reports in line with the EFPIA Disclosure Code. Reports may appear in the country’s local language. For translations or other enquiries, contact names have been provided. Please note there may be slight differences between disclosures figures reported on this page versus other sources (such as the UK’s ABPI disclosure platform for example). Please see the methodological notes for further explanation of what we are disclosing. Please view the infographic displaying an overview of GSK’s approach to transparency and break down of the combined total of spend / ToV to; - Unique HCP’s (named individual and aggregate) - Unique HCO’s (named individual and aggregate) - Research aggregate, if applicable Find out how disclosing information on payments made to doctors has already had positive effects in Europe. Find out more USA We were one of the first pharmaceutical companies in the USA to voluntarily disclose information about our work with physicians Rest of the world We continue to support and work towards transparency as industry associations or governments establish specific guidelines for disclosure around the world Compassionate use (Expanded access) Our policy explains our position and criteria for assessing requests and provides a link for health care professionals’ requests. Our behaviour We are changing the way we work to further embed our values in everything we do, including the way we research, develop, sell and market our products